Are cholesterol-lowering medications and antihypertensive agents preventing stroke in ways other than by controlling the risk factor?

Current Atherosclerosis Reports

Volumn 5, Issue 1, 2003, Pages 38-43

  Ruland, Sean ^a   Gorelick, Philip B ^a  

^a RUSH MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CHOLESTEROL; CLOFIBRATE; COMPACTIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; INDAPAMIDE; PERINDOPRIL; PRAVASTATIN; RAMIPRIL; SIMVASTATIN;

ANTIINFLAMMATORY ACTIVITY; BLOOD PRESSURE REGULATION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG MECHANISM; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; PLEIOTROPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION; STROKE; THROMBOSIS PREVENTION; VASOMOTOR REFLEX; CEREBROVASCULAR ACCIDENT; HYPERCHOLESTEROLEMIA; RISK FACTOR;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CEREBROVASCULAR ACCIDENT; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERTENSION; RISK FACTORS;

EID: 0038048903     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-003-0067-1     Document Type: Review

References (52)

1. Gorelick PB: Stroke prevention therapy beyond antithrombotics: unifying mechanisms in ischemic stroke pathogenesis and implications for therapy. An invited review. Stroke 2002, 33:862-875.
2. Ross R: Atherosclerosis: an inflammatory disease. N Engl J Med 1999, 340:115-126.
3. Amarenco P: Hypercholesterolemia, lipid-lowering agents, and the risk for brain infarction. Neurology 2001, 57(5 suppl 2):S35-S44.
4. Benfante R, Yano K, Hwang LJ, et al.: Elevated serum cholesterol is a risk factor for both coronary heart disease and thromboembolic stroke in Hawaiian Japanese men. Implications of shared risk. Stroke 1994, 25:814-820.
5. Hachinski V, Graffagnino C, Beaudry M, et al.: Lipids and stroke: a paradox resolved. Arch Neurol 1996, 53:303-308.
6. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
7. Sacks FM, Pfeffer MA, Moye LA, et al.: The effect of pravastatin on coronary events after myocardial infaretion in patients with average cholesterol levels. N Engl J Med 1996, 335:1001-1009.
8. White HD, Simes RJ, Anderson NE, et al.: Pravastatin therapy and the risk of stroke. N Engl J Med 2000, 343:317-326.
9. Heart Protection Study Collaborative Group: The MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002, 360:7-22.
10. Di Mascia R, Marchioli R, Tognoni C: Cholesterol reduction and stroke: an overview of randomized clinical trials. Cerebrovasc Dis 2000, 10:85-92.
11. Hebert PR, Gaziano JM, Chan KS, Hennekens CH: Cholesterol lowering with statin drugs, risk of stroke, and total mortality. JAMA 1997, 278:313-321.
12. Blauw GJ, Lagaay AM, Smelt AH, Westendrop RG: Stroke, statins, and cholesterol. Stroke 1997, 28:946-950.
13. Atkins D, Psaty BM, Koepsell TD, Longstreth WT Jr, Larson EB: Cholesterol reduction and the risk for stroke in men: a metaanalysis of randomized, controlled trials. Ann Intern Med 1993, 119:136-145.
14. Hebert PR, Gaziano JM, Hennickens CH, et al.: An overview of trials of cholesterol lowering and risk of stroke. Arch Intern Med 1995, 155:50-55.
15. Hess DC, Demchuk AM, Brass LM, Yatsu FM: HMG-CoA reductase inhibitors (statins): a promising approach to stroke prevention. Neurology 2000, 54:790-796.
16. Rosenson RS, Tangney CC: Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998, 279:1643-1650.
17. Crisby M, Nordin-Fredriksson G, Shah PK, et al.: Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implication for plaque stabilization. Circulation 2001, 103:926-933.
18. Ridker PM, Rifai N, Pfeffer MA, et al.: Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998, 98:839-844.
19. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E: Longterm effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999, 100:230-235.
20. Anderson TJ, Meredith IT, Yeung AC, et al.: The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995, 332:488-493.
21. Sterzer P, Meintzschel F, Rosler A, et al.: Pravastatin improves cerebral vasomotor reactivity in patients with subcortical small-vessel disease. Stroke 2001, 32:2817-2820.
22. Amin-Hanjani S, Stagliano NE, Yamada M, et al.: Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke 2001, 32:980-986.
23. Laufs U, Gertz K, Huang P, et al.: Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic Mice. Stroke 2000, 31:2437-2449.
24. Alfon J, Royo T, Garcia-Moll X, Badimon I.: Platelet deposition on eroded vessel walls at a stenotic shear rate is inhibited by lipid-lowering treatment with atorvastatin. Arterioscler Thromb Vasc Biol 1999, 19:1812-1817.
25. Weber KT: Aldosterone in congestive heart failure. N Engl J Med 2001, 345:1689-1697.
26. Farmer JA, Torre-Amione G: The renin-angiotensin system as a risk factor for coronary artery disease. Curr Atheroscler Rep 2001, 3:117-124.
27. Gibbons GH, Dzau VJ: The emerging concept of vascular remodeling. N Engl J Med 1994, 330:1431-1438.
28. Dzau VJ: Mechanism of protective effects of ACE inhibition on coronary artery disease. Eur Heart J 1998, 19(suppl J): J2-J6.
29. Gerbrondt KR, Yedinak KC: Formulary management of ACE inhibitors. Pharmacoeconomics 1996, 10:594-613.
30. Furberg CD, Pitt B: Are all angiotensin-converting enzyme inhibitors interchangeable? J Am Coll Cardiol 2001, 37:1456-1460.
31. Cohn JN: ACE inhibition and vascular remodeling of resistance vessels. Vascular compliance and cardiovascular implications. Heart Disease 2000, 2:S2-S6.
32. Schwartz Kopff B, Beh M, Mundhenke M, Strauer BE: Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease. Hypertension 2000, 36:220-225.
33. Sihm I, Schroeder AP, Aalkjaer C, et al.: Normalization of structural cardiovascular changes during antihypertensive treatment with a regimen based on the ACE-inhibitor perindopril. Blood Pressure 1995, 4:241-248.
34. Thybo NK, Stephens N, Cooper A, et al.: Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension 1995, 25(part 1):475-478.
35. Walters MR, Bolster A, Dyker AG, Lees KR: Effect of perindopril on cerebral and renal perfusion in stroke patients with carotid disease. Stroke 2001, 32:473-478.
36. Gorelick PB: New horizons for stroke prevention: PROGRESS and HOPE. Lancet 2003, in press.
37. MacMahon S, Peto R, Cutler J, et al.: Blood pressure, stroke, and coronary heart disease. Part I, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990, 335:765-774.
38. Collins R, Peto R, MacMahon S, et al.: Blood pressure, stroke and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomized drug trials in their epidemiologic context. Lancet 1990, 335:827-838.
39. Staessen JA, Wang JG, Thijs L: Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001, 358:1305-1315.
40. Blood Pressure Lowering Treatment Trialists' Collaboration: Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overview of randomized trials. Lancet 2000, 355:1955-1964.
41. Hansson L, Lindholm LH, Niskanen L, et al.: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet 1999, 353:611-616.
42. Punzi HA, Zusman R: Part II, Specific angiotensin-converting enzyme inhibitors, captopril. In Cardiovascular Drug Therapy, edn 2. Edited by Messerli FH. Philadelphia: WB Saunders, 1996:726-742.
43. PROGRESS Collaborative Group: Randomized trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet 2001, 358:1033-1041.
44. Bosch J, Yusuf S, Pogue J, et al.: Use of ramipril in preventing stroke: double blind randomized trial. BMJ 2002, 324:699-702.
45. Svensson P, deFaire U, Sleight P, Yusuf S, Ostergren J: Comparative effects of ramipril on ambulatory and office blood pressures. A HOPE substudy. Hypertension 2001, 38:e28-e32.
46. Sempos CT, Cleeman JI, Carroll MD: Prevalence of high blood cholesterol among US adults: an update based on guidelines from the Second Report of the National Cholesterol Education Program Adult Treatment Panel. JAMA 1993, 269:3009-3014.
47. Burt VL, Whelton P, roccella EJ, et al.: Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995, 25:305-313.
48. Goldstein LB, Adams R, Becker K, et al.: Primary prevention of ischemic stroke: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke 2001, 32:280-299.
49. Wolf PA, Clagett GP, Easton JD, et al.: Preventing ischemic stroke in patients with prior stroke and transient ischemic attack: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke 1999, 30:1991-1994.
50. Gorelick PB, Sacco RL: Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. JAMA 1999, 281:1112-1120.
51. The Sixth Report of the joint National Committee on Hypertension (JNC VI). Arch Intern Med 1997, 157:2413-2446.
52. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.